Personalised portfoliosPricing and feesAbout usHelp center
Healthcare

Healthcare

Companies advancing medical treatments and health services

0 items
Valuation
Price
TXG
10x Genomics, Inc. Class A Common Stock
TXG
33
$2.41B
-
$18.64
-0.11%
FDMT
4D Molecular Therapeutics, Inc. Common Stock
FDMT
33
$460.09M
-
$9.53
7.26%
SXTP
60 Degrees Pharmaceuticals, Inc. Common Stock
SXTP
61
$3.24M
-
$2.98
-6.54%
ETNB
89bio, Inc. Common Stock
ETNB
50
$2.20B
-
$14.95
0.10%
ABBV
ABBVIE INC.
ABBV
22
$397.33B
-
$228.95
2.09%
ABVC
ABVC BioPharma, Inc. Common Stock
ABVC
11
$38.39M
-
$1.35
-7.95%
ACIU
AC Immune SA Common Stock
ACIU
22
$321.23M
-
$2.50
0.20%
ACAD
ACADIA Pharmaceuticals Inc. Common Stock
ACAD
77
$4.06B
-
$24.95
3.17%
ADCT
ADC Therapeutics SA
ADCT
38
$507.90M
-
$4.41
7.56%
ADMA
ADMA Biologics Inc Common Stock
ADMA
55
$3.83B
-
$16.25
1.24%
AIM
AIM ImmunoTech Inc.
AIM
11
$4.18M
-
$1.06
1.43%
ALTS
ALT5 Sigma Corporation Common Stock
ALTS
50
$181.93M
-
$1.32
-9.02%
ALXO
ALX Oncology Holdings Inc. Common Stock
ALXO
27
$321.43M
-
$2.46
-1.63%
AMN
AMN Healthcare Services
AMN
33
$742.15M
-
$20.81
7.76%
ANTX
AN2 Therapeutics, Inc. Common Stock
ANTX
44
$28.50M
-
$1.05
0.96%
ANIP
ANI Pharmaceuticals, Inc.
ANIP
50
$1.75B
-
$75.09
-3.45%
SPRY
ARS Pharmaceuticals, Inc. Common Stock
SPRY
44
$889.64M
-
$9.21
2.44%
AARD
Aardvark Therapeutics, Inc. Common Stock
AARD
44
$268.25M
-
$12.58
1.95%
ABCL
AbCellera Biologics Inc. Common Shares
ABCL
50
$909.98M
-
$3.08
-0.16%
ABT
Abbott Laboratories
ABT
22
$195.12B
-
$115.20
2.70%
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

Have any questions or just want to keep in touch?

Follow us on LinkedIn

Chat on WhatsApp

[email protected]

*T&Cs apply

Fees SchedulePrivacy & Cookies PolicyTerms & Conditions

Cusp Wealth is a DFSA-regulated company with a Category 4 license to serve retail clients under license number 10863 and reference number F011420. We are authorised to advise on financial products and arrange deals in investments. Any information presented here is of a general nature and does not take into account your personal circumstances or financial objectives. All materials used in these communications are for marketing purposes of the Cusp Wealth Application; none are meant to offer to sell, a solicitation of an offer to buy, or a recommendation of any security or other financial instrument. They are not intended to provide investment, other financial, legal, tax, or other advice. Investments involve market volatility, possible capital loss, liquidity limits, and regulatory changes. Past performance of financial products is not a reliable indicator of future results. The value of investments can go down as well as up, and you may lose all or part of your capital. No content from Cusp Wealth should be understood as guaranteeing returns, offering risk-free investments, or promising wealth outcomes. This material is intended for DFSA-defined Retail and/or Professional Clients. If you are unsure of your classification or eligibility, please contact us at support@сuspwealth.com.

For interested persons, certain products and services are structured according to Islamic principles and approved under our DFSA-issued Islamic Endorsement. For more details, please refer to our full disclosure at https://cuspwealth.com/terms-and-conditions.